A Prospective International Multicenter Phase II Study to Evaluate the Efficacy, Safety and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Previous Therapy With Checkpoint Inhibitor Treatment
Latest Information Update: 23 Mar 2023
Price :
$35 *
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms IO-PAZ
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 30 Aug 2021 Status changed from active, no longer recruiting to completed.
- 14 Apr 2021 Planned End Date changed from 15 Jul 2021 to 13 Aug 2021.
- 21 Nov 2020 This trial is Suspended in Germany, according to European Clinical Trials Database record.